Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(04): 566-569
DOI: 10.4103/ijmpo.ijmpo_276_19
Report on International Publication

Interim-Response-Adapted Therapy in Advanced Hodgkin’s Lymphoma: Current Status

Prasanth Ganesan
Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

It has been 6 years after our initial publication of a phase II trial of response-adapted therapy (RAT) in advanced Hodgkin’s lymphoma (aHL), which was one of the first prospective studies published using RAT in aHL.[1] We had treated patients with aHL (defined as Stage IIB, III, and IV) with two cycles of ABVD and then performed an interim positron emission tomography/computed tomography (iPET-CT) scan iPET2. Those who had a Deauville score (DS) of 4 or 5 received four cycles of escalated BEACOPP (EB) and those with DS 1–3 continued 4 more ABVD. The disease-free survival (DFS) at 2 years was 76%, and overall survival (OS) was 88%. With more mature follow-up, the DFS at 5 years was 77%, and OS was 85% for the entire cohort of 50 patients.[2] The survival was inferior among iPET2+ (5-year DFS [50%] and OS [62%]) versus iPET2-−ve patients (5-year DFS [82%] and OS [85%]). These results have been replicated in much larger multicenter studies globally, and RAT has been accepted as one of the standard modes of treatment in aHL.



Publication History

Received: 28 December 2019

Accepted: 06 January 2020

Article published online:
03 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ganesan P, Rajendranath R, Kannan K, Radhakrishnan V, Ganesan TS, Udupa K. et al. Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin’s lymphoma. Ann Oncol 2015; 26: 1170-4
    CrossrefPubMedGoogle Scholar
  • 2 Ganesan P, Sagar T, Radhakrishnan V, Dhanushkodi M. Response-adapted therapy in Hodgkin’s lymphoma: Long-term follow up of a phase II clinical trial. Clin Lymphoma Myeloma Leuk 2018; 18: S231
    CrossrefGoogle Scholar
  • 3 Ganesan P, Kumar L, Raina V, Sharma A, Bakhshi S, Sreenivas V. et al. Hodgkin’s lymphoma—long-term outcome: An experience from a tertiary care cancer center in North India. Ann Hematol 2011; 90: 1153-60
    CrossrefPubMedGoogle Scholar
  • 4 Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003; 348: 2386-95
    CrossrefPubMedGoogle Scholar
  • 5 Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M. et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52
    CrossrefPubMedGoogle Scholar
  • 6 Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F. et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011; 152: 551-60
    CrossrefPubMedGoogle Scholar
  • 7 Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: Definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009; 50: 1761-4
    CrossrefPubMedGoogle Scholar
  • 8 Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-60
    CrossrefPubMedGoogle Scholar
  • 9 Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M. et al. US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest oncology group S0816. J Clin Oncol 2016; 34: 2020-7
    CrossrefPubMedGoogle Scholar
  • 10 Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M. et al. Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019; 134: 1238-46
    CrossrefPubMedGoogle Scholar
  • 11 Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A. et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 2016; 374: 2419-29
    CrossrefPubMedGoogle Scholar
  • 12 Rotman J, Fossa A, Federico M. Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: Longer follow up confirms efficacy of de-escalation after a negative interim pet scan (CRUK/07/033). Hematol Oncol 2017; 35: 65-7
    CrossrefGoogle Scholar
  • 13 Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A. et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol 2018; 36: 454-62
    CrossrefPubMedGoogle Scholar
  • 14 Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA. et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2018; 390: 2790-802
    CrossrefPubMedGoogle Scholar
  • 15 Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A. et al. Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: Final results of the phase II part of the HD0801 study. J Clin Oncol 2016; 34: 1376-85
    CrossrefPubMedGoogle Scholar
  • 16 Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202-15
    CrossrefPubMedGoogle Scholar
  • 17 Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M. et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014; 99: 1107-13
    CrossrefPubMedGoogle Scholar
  • 18 Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F. et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin’s lymphoma: A retrospective, European, multicentre cohort study. Lancet Haematol 2016; 3: e467-e479
    CrossrefPubMedGoogle Scholar
  • 19 Ganesan P, Dhanushkodi M, Ganesan TS, Radhakrishnan V, Kannan K, Sundersingh S. et al. Prognostic utility of the IPS 3 score for predicting outcomes in advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2019; 19: 116-22
    CrossrefPubMedGoogle Scholar
  • 20 Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K. et al. Does interim PET scan after 2 cycles of ABVD predict outcome in Hodgkin lymphoma? Real-world evidence. J Glob Oncol 2019; 5: 1-3
    CrossrefPubMedGoogle Scholar